Skip to main content
. 2013 Jan 14;32(47):5429–5438. doi: 10.1038/onc.2012.590

Figure 6.

Figure 6

Inhibition of RMS cell growth in vitro with dasatinib exposure. The RD (a) and Rh30 (b) cell lines were treated with dasatinib at different doses for 72 h. Each data point represents an average of six wells. (c) Dasatinib treatment decreased phosphorylation of SFK (tyr 416), as well as phosphorylation of CRKL (tyr207) at 250 nm for 72 h. (d) and (e) show that RD and Rh30 xenograft tumor growth is inhibited by dasatinib treatment. Western blot analysis of the tumors obtained from four mice in each of the control and the treated groups showed dasatinib treatment inhibits CRKL phosphorylation in both RD xenografts (f) and Rh30 xenografts (g) tumors. Normal mouse muscle shows minimal baseline pCRKL expression (f). (h) Cells transfected with mutant src (ck-src) are resistant to dasatinib inhibibition of CRKL phosphorylation and resistances to dasatinib growth inhibition (i and j).